Precision BioSciences, Inc. (DTIL), a clinical-stage gene editing company, on Wednesday shared promising initial data from its Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV, a novel gene editing therapy for chronic Hepatitis B.
The PBGENE-HBV therapy, which is delivered via a lipid nanoparticle or LNP encapsulated ARCUS mRNA, was found to be safe and well-tolerated in all three participants at the lowest dose level 0.2 mg/kg after the first administration.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.